Entera Bio (ENTX) Competitors $2.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.00 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. ARCT, CRVS, ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, and NGNEShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Arcturus Therapeutics (NASDAQ:ARCT) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Which has stronger earnings & valuation, ARCT or ENTX? Entera Bio has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$109.80M4.43-$80.94M-$2.23-8.03Entera Bio$180K507.33-$9.54M-$0.26-7.69 Do analysts prefer ARCT or ENTX? Arcturus Therapeutics currently has a consensus target price of $50.00, indicating a potential upside of 179.17%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 400.00%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Entera Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is ARCT or ENTX more profitable? Arcturus Therapeutics has a net margin of -49.26% compared to Entera Bio's net margin of -4,525.11%. Arcturus Therapeutics' return on equity of -24.87% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-49.26% -24.87% -17.75% Entera Bio -4,525.11%-77.75%-68.13% Do insiders and institutionals believe in ARCT or ENTX? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 10.4% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ARCT or ENTX? Arcturus Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Does the media refer more to ARCT or ENTX? In the previous week, Arcturus Therapeutics had 21 more articles in the media than Entera Bio. MarketBeat recorded 34 mentions for Arcturus Therapeutics and 13 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.82 beat Arcturus Therapeutics' score of 0.55 indicating that Entera Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 4 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArcturus Therapeutics beats Entera Bio on 9 of the 17 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.32M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-7.6920.7630.8625.25Price / Sales507.33231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book8.709.759.516.00Net Income-$9.54M-$54.74M$3.26B$265.34M7 Day Performance6.38%8.09%4.49%2.81%1 Month Performance-2.44%7.70%5.18%1.50%1 Year Performance22.70%18.13%31.98%25.46% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio1.0723 of 5 stars$2.00flat$10.00+400.0%+22.7%$91.32M$180K-7.6920Short Interest ↑ARCTArcturus Therapeutics2.8813 of 5 stars$11.39-4.4%$50.80+346.0%-3.6%$323.01M$152.31M-4.50180Earnings ReportHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9019 of 5 stars$4.37+1.4%$15.00+243.2%+32.4%$321.15MN/A-4.3330ABEOAbeona Therapeutics4.5665 of 5 stars$6.28+0.3%$19.25+206.5%+42.6%$320.24M$3.50M-4.9490News CoverageEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals2.1336 of 5 stars$4.57-1.5%$24.50+436.1%-54.9%$317.48MN/A-2.2770Earnings ReportALDXAldeyra Therapeutics2.0457 of 5 stars$5.25-0.2%$9.50+81.0%+6.3%$315.05MN/A-6.1810AMRNAmarin0.254 of 5 stars$14.94-0.3%$12.00-19.7%+26.9%$310.40M$228.61M-4.07360BNTCBenitec Biopharma1.7364 of 5 stars$11.90+0.8%$26.00+118.5%+47.7%$309.76M$80K-7.8820News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8468 of 5 stars$2.92+2.1%$16.33+459.4%-83.9%$308.61MN/A-1.16240INBXInhibrx Biosciences1.6567 of 5 stars$21.40+1.6%N/A+87.2%$304.86M$200K0.18166News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↓NGNENeurogene2.001 of 5 stars$20.35-4.1%$46.17+126.9%-41.4%$302.64M$930K-4.6890Earnings Report Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Corvus Pharmaceuticals Competitors Abeona Therapeutics Competitors Olema Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Amarin Competitors Benitec Biopharma Competitors Rocket Pharmaceuticals Competitors Inhibrx Biosciences Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access